Related Experiment Video
Updated: Apr 18, 2026

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration
Published on: May 19, 2016
The phosphoinositide-binding protein TRAF4 modulates tight junction stability and migration of cancer cells
Adrien Rousseau1, Léa P Wilhelm2, Catherine Tomasetto2
1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC); Functional Genomics and Cancer Department ; Illkirch, France ; Institut National de la Santé et de la Recherche Médicale (INSERM) ; Illkirch, France ; Centre National de la Recherche Scientifique (CNRS) ; Illkirch, France ; Université de Strasbourg ; Illkirch, France ; Present address: MRC Laboratory of Molecular Biology ; Cambridge, UK.
Abstract:
Tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4), a protein localized in TJs in normal epithelial cells, is frequently overexpressed in carcinomas. We recently found that TRAF4 impedes TJ formation/stability and favors cell migration, 2 hallmarks of cancer progression. In addition TRAF4 contributes to the TGF-β-induced epithelial-mesenchymal transition (EMT), metastasis, and p53 destabilization. TRAF4 recruitment to TJs is a prerequisite for its biological function on TJ formation/stability and on cell migration. Interestingly, TRAF4 is targeted to TJs through lipid-binding. The trimeric TRAF domain of TRAF4 binds 3 phosphoinositide (PIP) molecules. These findings shed new light on the role of TRAF4 in cancer progression; they provide a novel link between lipid metabolism and cancer progression and support the notion that TRAF4 could be a relevant target for cancer therapies. TRAF4 belongs to a family of 7 human proteins involved in different biological processes, such as inflammation, immunity and embryonic development. While the lipid-binding ability of the TRAF domain is conserved among the whole TRAF protein family, its functional role remains to be established for the remaining TRAF proteins.
Insights
Tumor necrosis factor-associated factor 4 (TRAF4) protein overexpression in carcinomas impedes cell junctions and promotes cancer progression. TRAF4
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4) is overexpressed in carcinomas.
- TRAF4 localizes to tight junctions (TJs) in normal epithelial cells.
- TRAF4 impedes TJ formation/stability and promotes cell migration, key aspects of cancer progression.
Purpose of the Study:
- To investigate the role of TRAF4 in cancer progression.
- To elucidate the mechanism of TRAF4 recruitment to TJs.
- To explore TRAF4 as a potential therapeutic target.
Main Methods:
- Investigated TRAF4's function in TJ formation, stability, and cell migration.
- Examined TRAF4's contribution to TGF-β-induced epithelial-mesenchymal transition (EMT) and metastasis.
- Studied TRAF4 recruitment to TJs via lipid-binding and its interaction with phosphoinositides (PIPs).
Main Results:
- TRAF4 overexpression impedes TJ formation/stability and enhances cell migration.
- TRAF4 promotes TGF-β-induced EMT, metastasis, and p53 destabilization.
- TRAF4 is recruited to TJs through lipid-binding, interacting with 3 PIP molecules via its trimeric TRAF domain.
Conclusions:
- TRAF4 plays a significant role in cancer progression by disrupting TJs and promoting cell migration and metastasis.
- TRAF4's lipid-binding ability is crucial for its function and represents a novel link between lipid metabolism and cancer.
- TRAF4 is a potential therapeutic target for cancer treatment, and its lipid-binding function may be conserved across the TRAF protein family.
More Related Videos
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Cancer Cell Migration through Invadopodia
Tight Junctions
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression

